MYGN

Myriad Genetics Inc.

Price

$3.19

return (12m)

-42.11%

p/e

-2.64

p/bv

0.98

DIVIDEND YIELD

0.00%

MYGN price

Myriad Genetics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment MYGN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-45.84%

3 months

-18.41%

1 year

-42.11%

2 years

-88.71%

5 years

-90.94%

10 years

-84.90%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals MYGN

Valuation

P/E

-2.64

Sector -4.38

Industry -4.38

P/BV

0.98

Sector 2.02

Industry 2.02

P/Revenue (PSR)

0.37

Sector -4.40

Industry -4.40

EV/EBITDA

-11.67

Sector -263.09

Industry -263.09

EV/EBIT

-7.88

Sector -702.90

Industry -702.90

P/EBITDA

-6.59

Sector -4.39

Industry -4.39

P/EBIT

-3.12

Sector -4.73

Industry -4.73

P/Total Assets

0.47

Sector 1.49

Industry 1.49

P/Net Current Assets

-6.47

Sector -11.70

Industry -11.70

P/Working Capital

1.88

Sector -3.19

Industry -3.19

EPS

-1.19

Sector -2.14

Industry -2.14

BVPS

3.20

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

68.83%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-13.63%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-20.19%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-11.22%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-13.96%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.30

Sector 0.03

Industry 0.03

Profitability

ROE

-37.05%

Sector -65.14%

Industry -65.14%

ROA

-17.62%

Sector -65.53%

Industry -65.53%

ROIC

-34.37%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.21

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-0.21

Sector -6.07

Industry -6.07

Net Debt / EBIT

-0.14

Sector -8.26

Industry -8.26

Net Debt / Equity

0.02

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.40

Sector -0.05

Industry -0.05

Equity/Assets

0.48

Sector 0.41

Industry 0.41

Liabilities/Assets

0.52

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

3.15%

Sector -

Industry -

5Y Earnings CAGR

32.86%

Sector -

Industry -

Fundamentals MYGN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
MYGN Myriad Genetics Inc.	$3.19	-44.13%	0.00%	-2.64	0.98	-37.05%	-13.96%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

MYGN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Myriad Genetics

Myriad Genetics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

34 years

Founded: 1992

1995

Time since IPO - 31 years

27.000

Employees

Myriad Genetics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $297.83 million, with shareholders equity totaling $303.90 million.

The company employs approximately 27.000 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Myriad Genetics Inc. reported $806.60 million in revenue, generating net income of $-112.60 million.

Key financial metrics include a P/E ratio of -2.64, a price-to-book (P/B) ratio of 0.98, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker MYGN.

Market cap

$297.83 million

Net worth

$303.90 million

$303,900,000.00

Assets

$638.90 million

$638,900,000.00

Total Shares Outstanding

95.00 million

95,000,000

Average Daily Trading Volume

$1.88 million

$1,877,880.00

Sector

Health Care

Industry

Biotechnology

MYGN

MYGN revenue and profits

Financial Results MYGN

DRAG THE FRAME TO SEE MORE DATA

MYGN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Myriad Genetics (MYGN) today?

A cotação de Myriad Genetics (MYGN) hoje está em US$ 3.19, com uma variação de -42.11% em relação ao último ano. A cotação de Myriad Genetics (MYGN) iniciou o ano negociando na casa dos US$ 6.15 e hoje está em US$ 3.19. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Myriad Genetics (MYGN) e dados de ações do Ibovespa e mercados internacionais.

Quando Myriad Genetics (MYGN) paga dividendos?

Myriad Genetics (MYGN) não distribuiu dividendos no último ano.

Is Myriad Genetics (MYGN) a good investment?

Atualmente, Myriad Genetics (MYGN) está cotada a US$ 3.19, com um P/L de -2.64, representando um desvio de -614% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -42.11 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -42.11%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Myriad Genetics (MYGN) stock?

Investir em ações de Myriad Genetics (MYGN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Myriad Genetics (MYGN) yield today?

A rentabilidade de Myriad Genetics (MYGN) foi de -45.84% no último mês, -42.11% no último ano e -90.94% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Myriad Genetics (MYGN) hoje, o investimento total seria de US$ 319.00, com base na cotação atual de US$ 3.19.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 184.67
Em 5 anos: US$ 28.90
Em 10 anos: US$ 48.17

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

MYGN

Myriad Genetics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment MYGN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING MYGN WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Myriad Genetics

Myriad Genetics Inc.

United States

34 years

1995

27.000

PROFIT X PRICE MYGN

Financial Results MYGN

MYGN cash flow

Asset, Revenue and Profit Growth - MYGN

MYGN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions